Diabetic Macular Edema (DME)
Ophthalmology
Prevalence
81.8 / 100K
8 drugs in development·6 companies·5 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| ILUVIEN | ANI PHARMACEUTICALS INC (ANIP) |
Phase 3(1)
| Drug | Company |
|---|---|
| m710 | MOMENTA PHARMACEUTICALS INC (MNTA) |
Phase 1(2)
Preclinical(1)
| Drug | Company |
|---|---|
| szn-8141 | Surrozen Inc. (SRZN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Diabetic Macular Edema (DME)?
BioSniper tracks 8 drugs in development for Diabetic Macular Edema (DME) across 6 companies.
How many clinical trials target Diabetic Macular Edema (DME)?
There are 5 clinical trials targeting Diabetic Macular Edema (DME) tracked by BioSniper.
What is the prevalence of Diabetic Macular Edema (DME)?
The estimated prevalence of Diabetic Macular Edema (DME) is approximately 81.8 per 100,000 population.
Deep-dive into Diabetic Macular Edema (DME)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis